Cidara Therapeutics, Inc. secures funding and focuses on oncology platform after passing rezafungin rights to Mundipharma.
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary ...
Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) ...